0000000000239003
AUTHOR
E. Del Pozo
VizieR Online Data Catalog: 46 open clusters GaiaDR2 HR diagrams (Gaia Collaboration, 2018)
We have determined the membership of 46 open clusters. For the nine clusters within 250pc we determined optimised parallaxes based on the combined information extracted from the measured parallax and proper motion values. These clusters are : in Tables A1a & A3: alphaPer, Blanco1, ComaBer, Hyades, IC2391, IC2602, NGC2451A, Pleiades, Praesepe. The remaining 37 clusters are in Table A1b & A4: Coll140, IC4651, IC4665, IC4725, IC4756, NGC0188, NGC0752, NGC0869, NGC0884, NGC1039, NGC1901, NGC2158, NGC2168, NGC2232, NGC2323, NGC2360, NGC2422, NGC2423, NGC2437, NGC2447, NGC2516, NGC2547, NGC2548, NGC2682, NGC3228, NGC3532, NGC6025, NGC6281, NGC6405, NGC6475, NGC6633, NGC6774, NGC6793, NGC7092, Sto…
VizieR Online Data Catalog: Gaia DR2 sources in GC and dSph (Gaia Collaboration+, 2018)
The files contains lists of possible members of each of the objects (75 globular clusters, 9 dwarf spheroidal galaxies, the Bootes I UFD, the LMC and SMC). The stars in these lists have been selected and used to determine the astrometric parameters of the corresponding objects following either the procedures described in Sec. 2.1 (for the clusters and dwarfs) or in Sec. 2.2 (for the LMC and SMC). The first column is the "source_id" as given by Gaia, the ra and declination of the star in degrees, and its G-band magnitude (known as "photgmean_mag" in the Gaia archive). (2 data files).
Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995 over 6 months.
This study examined the effects of the long-acting selective mini somatostatin analogue (SMS) 201-995 in two acromegalic patients who were treated for 3 and 6 months, respectively. During treatment the mean growth hormone levels (25.3 and 20.8 ng/ml vs 5.9 and 10.6 ng/ml) and somatomedin C levels (6.2 and 6.2 IU/ml vs 3.3 and 3.8 IU/ml) decreased and the patients reported an improvement in their symptoms. The main side effect was an increase in stool fat excretion which did exceed the normal range (less than 7 g/day) in one patient. Five acromegalics who received 2 X 50 micrograms SMS 201-995/day for 5 days showed a significant increase of stool fat excretion (1.7 vs 3.5 g/day; p less than …
LONG-ACTING AND SELECTIVE SUPPRESSION OF GROWTH HORMONE SECRETION BY SOMATOSTATIN ANALOGUE SMS 201-995 IN ACROMEGALY
In 6 of 7 acromegalic patients a single subcutaneous injection of 50 micrograms of a new octapeptide somatostatin analogue (SMS 201-995) reduced serum growth hormone (GH) from 30 +/- 12 ng/ml to 1.4 +/- 0.4 (mean +/- SEM). Serum GH remained below basal concentration for 9 h. In the remaining patient who had very high basal preprandial serum GH, SMS 201-995 produced a reduction in serum GH of only 20%. Plasma glucose concentrations were increased to the upper limits of the normal range when a high-carbohydrate meal was consumed 2 h after injection. In non-diabetic patients plasma glucose did not exceed 129 mg/dl. The 40% decrease in plasma glucagon, which lasted for 7 h after SMS 201-995 inj…